

# Manuela Liguori

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9442101/manuela-liguori-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9

papers

1,033

citations

6

h-index

10

g-index

10

ext. papers

1,210

ext. citations

6.9

avg, IF

3.07

L-index

#	Paper	IF	Citations
9	Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy. <i>European Journal of Immunology</i> , <b>2021</b> , 51, 2677-2686	6.1	1
8	Trabectedin, a Drug Acting on Both Cancer Cells and the Tumor Microenvironment. <i>Human Perspectives in Health Sciences and Technology</i> , <b>2020</b> , 287-300	0.3	
7	Cells with stemness features are generated from in vitro transformed human fibroblasts. <i>Scientific Reports</i> , <b>2018</b> , 8, 13838	4.9	5
6	Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 628-638	8.7	71
5	Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment. <i>Oncotarget</i> , <b>2016</b> , 7, 41662-41676	3.3	47
4	Pituitary Adenoma and the Chemokine Network: A Systemic View. <i>Frontiers in Endocrinology</i> , <b>2015</b> , 6, 141	5.7	11
3	Role of macrophage targeting in the antitumor activity of trabectedin. <i>Cancer Cell</i> , <b>2013</b> , 23, 249-62	24.3	568
2	Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. <i>Cancers</i> , <b>2011</b> , 3, 3740-61	6.6	54
1	Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. <i>Journal of Immunology</i> , <b>2010</b> , 185, 642-52	5.3	275